EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudieOpen Access · CC BY 4.0

An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer

Joseph R Habib iD, Ingmar F Rompen, Brady A Campbell, Paul C M Andel, Benedict Kinny-Köster, Ryte Damaseviciute, D Brock Hewitt, Greg D Sacks, Ammar A Javed, Marc G Besselink, Hjalmar C van Santvoort, Lois A Daamen und 5 weitere

JNCI: Journal of the National Cancer Institute · 2024

DOI: 10.1093/jnci/djae166 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Joseph R Habib und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, New York University Langone Health, New York, NY, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoplasm Staging, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Ben and Rose Cole Charitable PRIA Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intraductal papillary mucinous neoplasm (IPMN)–derived pancreatic ductal adenocarcinoma (PDAC) is resected at smaller sizes compared with its biologically distinct counterpart, pancreatic intraepithelial neoplasia (PanIN)–derived PDAC. Thus, experts proposed T1 sub-staging for IPMN-derived PDAC. However, this has never been validated.

Methods

Consecutive upfront surgery patients with IPMN-derived PDAC from 5 international high-volume centers were classified by the proposed T1 sub-staging classification (T1a ≤0.5, T1b >0.5 and ≤1.0, and T1c >1.0 and ≤2.0 cm) using the invasive component size. Kaplan-Meier and log-rank tests were used to compare overall survival (OS). A multivariable Cox regression was used to determine hazard ratios (HRs) with confidence intervals (95% CIs).

Results

Among 747 patients, 69 (9.2%), 50 (6.7%), 99 (13.0%), and 531 patients (71.1%), comprised the T1a, T1b, T1c, and T2-4 subgroups, respectively. Increasing T-stage was associated with elevated CA19-9, poorer grade, nodal positivity, R1 margin, and tubular subtype. Median OS for T1a, T1b, T1c, and T2-4 were 159.0 (95% CI = 126.0 to NR), 128.8 (98.3 to NR), 77.6 (48.3 to 108.2), and 31.4 (27.5 to 37.7) months, respectively (P < .001). OS decreased with increasing T-stage for all pairwise comparisons (all P < .05). After risk adjustment, older than age 65, elevated CA19-9, T1b [HR = 2.55 (1.22 to 5.32)], T1c [HR = 3.04 (1.60 to 5.76)], and T2-4 [HR = 3.41 (1.89 to 6.17)] compared with T1a, nodal positivity, R1 margin, and no adjuvant chemotherapy were associated with worse OS. Disease recurrence was more common in T2-4 tumors (56.4%) compared with T1a (18.2%), T1b (23.9%), and T1c (36.1%, P < .001).

Conclusion

T1 sub-staging of IPMN-derived PDAC is valid and has significant prognostic value. Advancing T1 sub-stage is associated with worse histopathology, survival, and recurrence. T1 sub-staging is recommended for future guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeoplasm StagingCarcinoma, Pancreatic DuctalHumansFemaleMaleAgedMiddle AgedPancreatic Intraductal NeoplasmsAdenocarcinoma, MucinousRetrospective StudiesKaplan-Meier EstimatePrognosisPancreatectomy

Autor:innen und Institutionen

  • Department of Surgery, New York University Langone Health, New York, NY, USA.
  • Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Surgery, Regional Academic Cancer Center Utrecht, Utrecht, The Netherlands.
  • Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA.
  • Department of Surgery, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.

ORCID-Profile: Joseph R Habib

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Ben and Rose Cole Charitable PRIA Foundation
  • NIH

Zitieren

APA

Habib, J. R., Rompen, I. F., Campbell, B. A., Andel, P. C. M., Kinny-Köster, B., Damaseviciute, R., Brock Hewitt, D., Sacks, G. D., Javed, A. A., Besselink, M. G., van Santvoort, H. C., Daamen, L. A., Loos, M., He, J., Quintus Molenaar, I., Büchler, M. W., & Wolfgang, C. L. (2024). An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae166

Vancouver

Habib JR, Rompen IF, Campbell BA, Andel PCM, Kinny-Köster B, Damaseviciute R, et al. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae166

BibTeX
@article{Habib2024,
  author = {Habib, Joseph R and Rompen, Ingmar F and Campbell, Brady A and Andel, Paul C M and Kinny-Köster, Benedict and Damaseviciute, Ryte and Brock Hewitt, D and Sacks, Greg D and Javed, Ammar A and Besselink, Marc G and van Santvoort, Hjalmar C and Daamen, Lois A and Loos, Martin and He, Jin and Quintus Molenaar, I and Büchler, Markus W and Wolfgang, Christopher L},
  title = {An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  doi = {10.1093/jnci/djae166}
}
Kostenlos starten →